Schering launches new dermatology company
pharmafile | February 8, 2005 | News story | Sales and Marketing |Â Â Â
German pharma company Schering has created a new, independent group, Intendis, focused on developing and marketing dermatology products.
Intendis' new management team said its aim was to become a top ten industry player, setting itself a target of increasing sales by more than 8 %, and boosting operating profit to 18 % of sales by 2006.
The company will remain a 100% owned subsidiary of Schering but will operate independently as a fully integrated pharmaceutical company, taking on the rights to Schering's dermatology brands.
The Berlin-based company's portfolio includes psoriasis treatment Psorcutan and Finacea, a topical product for the treatment of Rosacea – a disorder of the facial skin that affects an estimated 14 million Americans – which does not come off patent until 2018 and is expected to repeat its double-digit 2005 sales growth.
Schering has also been a pioneer in the development and introduction of corticosteroid ointments, like eczema treatment Advantan.
Intendis, which earned net sales of E200 million in 2004 and has a 300-strong salesforce, will be headed up by Professor Dr Wolfgang Kehr, previously managing director of the Centre of Dermatology at Schering.
"We are looking forward to growing Intendis into a major specialist dermatology company and to become a partner of choice in our field," said Prof Kehr.
"We expect that our strong brands and dedication to new product development will ensure sales growth above current market growth. We clearly aim to maximise the growth potential of our business."
He added that the UK was an "attractive market to exploit in terms of potential sales", and said the company was now looking for a strategic partner to create critical mass in major markets.
Prof Kehr is joined by, amongst others, former colleague, chief financial officer Dr Detlev Hessenbruch, and the management team says it will develop its markets throughout Europe and the US.
Related articles:
Schering restructures for long-term growth
Thursday , June 17, 2004
